Original Research Article | Published:

“Well, good luck with that”: reactions to learning of increased genetic risk for Alzheimer disease

Genetics in Medicine | Download Citation




Apolipoprotein-E (APOE) genetic testing to estimate risk for developing late-onset Alzheimer disease is increasingly being offered without prior genetic counseling or preparation. Consumer interest continues to grow, raising the question of how best to conduct such testing.


Twenty-six semistructured interviews were carried out to study the reactions of individuals who had already learned of their higher risk after APOE testing had been done because of a family history of Alzheimer disease, or from genetic tests done for other health-related or general-interest reasons.


Adverse psychological reactions were reported by a substantial fraction of the participants, including those who had specifically sought testing, those for whom the information came as a surprise, those with a family history, and those with no known history. Still, nearly all of those interviewed said that they had benefited in the long term from lifestyle changes, often learned from online sources, that they subsequently made.


The results show that people should be prepared prior to any genetic testing and allowed to opt out of particular tests. If testing is carried out and a higher risk is revealed, they should be actively assisted in deciding how to proceed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.

  2. 2.

    , , et al. APOE-e4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. J Neurol 1999;53:321–331.

  3. 3.

    , , et al. Incorporating ethnicity into genetic assessment for Alzheimer’s disease: the REVEAL study experience. Genet Med 2008;10:207–214.

  4. 4.

    & . Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol 2007;6:1106–1114.

  5. 5.

    Alzheimer disease overview. In: , , et al(eds). GeneReviews. University of Washington: Seattle, WA, 23 October 1998. Updated 24 September 2015.

  6. 6.

    American College of Medical Genetics, American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statement on the use of Apolipoprotein E testing for Alzheimer disease. JAMA 1995;274:1627–1629.

  7. 7.

    Medical and Scientific Advisory Committee and Alzheimer’s Disease International. Consensus statement on genetic testing for Alzheimer disease. Alzheimer Dis Assoc Disord 1995;9:182–87.

  8. 8.

    National Institute on Aging and Alzheimer’s Association Working Group. Apolipoprotein E genotyping in Alzheimer disease. Lancet 1996;347:1091–1095.

  9. 9.

    Choosing Wisely. ACMG Provides Recommendations on Genetic Testing Through the Choosing Wisely® Campaign. . 10 July 2015. Accessed 12 January 2018.

  10. 10.

    , , et al. Personal utility and genomic information: look before you leap. Genet Med 2009;11:575–576.

  11. 11.

    . To Test or Not to Test: A Consumer’s Guide to Genetic Screening and Risk. Rutgers University Press: New Brunswick, NJ, 2008: 73–107.

  12. 12.

    , , et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med 2009;361:245–254.

  13. 13.

    , & . Using Alzheimer’s disease as a model for genetic risk disclosure: implications for personal genomics. Clin Genet 2011;80:407–414.

  14. 14.

    , & . Characteristics of qualitative descriptive studies: a systemic review. Res Nurs Health 2017;40:23–42.

  15. 15.

    , , & . Qualitative description—the poor cousin of health research? BMC Med Res Methodol 2009;9:52.

  16. 16.

    & . Alzheimer’s disease: biomarkers in the genome, blood, and cerebrospinal fluid. Front Neurol 2017;8:102–116.

  17. 17.

    , , et al. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer’s disease: the REVEAL study. Genet Med 2006;8:746–751.

  18. 18.

    , , et al. Susceptibility genes and the question of embodied identity. Med Anthropol Q 2007;21:256–276.

  19. 19.

    National Society of Genetic Counselors, Genetic testing of minors for adult-onset conditions. 15 February 2017. . Accessed 12 January 2018.

  20. 20.

    Re/code Decode hosted by Kara Swisher. Interview with Anne Wojcicki released 3 April 2016. Accessed 12 January 2018.

  21. 21.

    US Food and Drug Administration. FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions. 6 April 6 2017. Accessed 12 January 2018.

  22. 22.

    & . Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet 1995;45:41–45.

  23. 23.

    . Does it Run in the Family? A Consumer’s Guide to DNA Testing for Genetic Disorders. Rutgers University Press: New Brunswick, NJ, 2008.

  24. 24.

    Huntington’s Disease Society of America. Genetic testing protocol for Huntington’s disease. 2016. . Accessed 12 January 2018.

  25. 25.

    American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. J. Clin Oncol. 2003;21:2397–406.

  26. 26.

    , , et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011;13:597–605.

  27. 27.

    , , et al. Attitudes and practices among internists concerning genetic testing. J Genet Counsel 2013;22:90–100.

  28. 28.

    & . Genomics education for health care professionals in the 21st century. JAMA 2011;306:989–990.

  29. 29.

    , , et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017;Issue 4. Art. no.: CD001431 doi:doi:10.1002/14651858.CD001431.pub5.

  30. 30.

    , , et al. Evaluation of a Web-based decision aid for people considering the APOE genetic test for Alzheimer risk. Genet Med 2017;19:676–682.

  31. 31.

    , , et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population n-based perspective. Alzheimers Dement 2015;11:718–726.

Download references


This study was supported in part by the Department of Science, Technology, and Society at Virginia Tech.

Author information


  1. Department of Science, Technology, and Society, Virginia Tech, Blacksburg, Virginia, USA, and Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA

    • Doris T Zallen


  1. Search for Doris T Zallen in:

Competing interests

The author declares no conflict of interest.

Corresponding author

Correspondence to Doris T Zallen.

About this article

Publication history